TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib: review proposal

Health Technology Appraisal

Review of NICE Technology Appraisal Guidance Nos 86 & 209; Imatinib for gastrointestinal stromal tumours and imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours

Proposal to move the existing guidance to the static list

The planned date for review of the above guidance is August 2013.

This is the date at which the Institute considers whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

There is limited new evidence available since the guidance was last reviewed but this new evidence does not warrant a review of NICE technology appraisal guidance 86 or 209, and we are not aware that studies are ongoing that would change this view in the near future.  Consequently we propose that both TA86 and 209 move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted. 

August 2013


This page was last updated: 01 October 2013